0000000000815620
AUTHOR
L. Stein
Extrakorporale Stoßwellenlithotripsie (ESWL) — Physikalische und biologische Grundlagen
Sieben Jahre sind inzwischen seit der ersten humanen ESWL-Behandlung im Februar 1980 vergangen, vier Jahre seit der Inbetriebnahme der 2. ESWL-Anlage hier in Stuttgart und damit seit dem Beginn der serienmasigen Verteilung der ESWL-Technologie, zunachst in der Bundesrepublik Deutschland, danach weltweit.
Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A Randomized Trial
International audience; Background & AimsTreatment of hepatitis C virus (HCV) infection with boceprevir, peginterferon, and ribavirin can lead to anemia, which has been managed by reducing ribavirin dose and/or erythropoietin therapy. We assessed the effects of these anemia management strategies on rates of sustained virologic response (SVR) and safety.MethodsPatients (n = 687) received 4 weeks of peginterferon and ribavirin followed by 24 or 44 weeks of boceprevir (800 mg, 3 times each day) plus peginterferon and ribavirin. Patients who became anemic (levels of hemoglobin approximately ≤10 g/dL) during the study treatment period (n = 500) were assigned to groups that were managed by ribavi…